Two phase ii randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2759-2770

  Kuna, Piotr ^a   Bjermer, Leif ^b   Tornling, Göran ^c,d  

^a Medical University of Łódz ^*  (Poland)

^b LUND UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CRTh2 receptor; Efficacy; Phase II; Prostaglandin D2; Respiratory; Th2 cells

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIASTHMATIC AGENT; AZD 1981; PLACEBO; THYROTROPIN; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; AZD1981; IMMUNOGLOBULIN RECEPTOR; INDOLE DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ANXIETY DISORDER; ARTICLE; ASTHMA; CHOLELITHIASIS; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ECZEMA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTRITIS; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; INFECTION; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEPHROLITHIASIS; NEUROSIS; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PYODERMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN ALLERGY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; YOUNG ADULT;

EID: 84985916151     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S105142     Document Type: Article

References (31)

1. Global Initiative for Asthma (GINA). GINA Report, Global Strategy for Asthma Management and Prevention. 2016. Available from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed June 2016.
2. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40–47.
3. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193(2):255–261.
4. Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999;459(2):195–199.
5. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol. 1999;162(3): 1278–1286.
6. O’Byrne PM, Naji N, Gauvreau GM. Severe asthma: future treatments. Clin Exp Allergy. 2012;42(5):706–711.
7. Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986; 315(13):800–804.
8. Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131(6):1504–1512.
9. Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108(6): 982–988.
10. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol. 2002;168(3):981–985.
11. Stubbs VE, Schratl P, Hartnell A, et al. Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem. 2002;277(29):26012–26020.
12. Shirasaki H, Kikuchi M, Kanaizumi E, Himi T. Accumulation of CRTH2-positive leukocytes in human allergic nasal mucosa. Ann Allergy Asthma Immunol. 2009;102(2):110–115.
13. + Th2 lymphocytes in response to mast cell supernatants. Immunology. 2006;119(3):362–368.
14. Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85(6):372–382.
15. Pettipher R, Hansel TT. Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect. 2008;21(6):317–322.
16. Xue L, Barrow A, Pettipher R. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells. Clin Exp Immunol. 2009;156(1):126–133.
17. Xue L, Gyles SL, Wettey FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175(10):6531–6536.
18. Heinemann A, Schuligoi R, Sabroe I, Hartnell A, Peskar BA. Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol. 2003;170(9):4752–4758.
19. Xue L, Barrow A, Pettipher R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2009;182(12): 7580–7586.
20. Lukacs NW, Berlin AA, Franz-Bacon K, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2008;295(5):L767–L779.
21. Stebbins KJ, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol. 2010;638(1–3):142–149.
22. Uller L, Mathiesen JM, Alenmyr L, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007;8:16.
23. Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44(8):1044–1052.
24. Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014;28(6): 690–699.
25. Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67(12):1572–1579.
26. Luker T, Bonnert R, Brough S, et al. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981. Bioorg Med Chem Lett. 2011;21(21):6288–6292.
27. Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41(1):46–52.
28. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42(1):38–48.
29. Schröder R, Xue L, Konya V, et al. PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One. 2012;7(3): e33329.
30. Busse WW, Wenzel SE, Meltzer EO, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol. 2013;131(2):339–345.
31. Nishikawa-Shimono R, Sekiguchi Y, Koami T, et al. Isoquinoline derivatives as potent CRTH2 receptor antagonists: synthesis and SAR. Bioorg Med Chem Lett. 2012;22(9):3305–3310.